Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
  • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
  • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
  • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
  • C07C279/22—Y being a hydrogen or a carbon atom, e.g. benzoylguanidines

Definitions

• the invention relates to compounds of the formula
• R 2 , R 3 , R ö each independently of one another H, A, OR 6 , N (R 6 ) 2 , NO 2l CN, Hai, NHCOA, NHCOAr, NHSO 2 A, NHSO 2 Ar, COOR 6 , CON (R 6 ) 2 , CONHAr, COR 6 , COAr, S (O) n A, S (O) n Ar, -O- [C (R 6 ) 2 ] m -COOR 6 , - [C (R 6 ) 2 ] p -COOR 6 , -O- [C (R 6 ) 2 ] m - CON (R 6 ) 2l - [C (R 6 ) 2 ] p -CON (R 6 ) 2 , -O- [C (R 6 ) 2 ] m -CONHAr, or - [C (R 6 ) 2 ] p -CONHAr,
• R b H, A or benzyl, - 2 -
• a alkyl with 1-20 C atoms, in which one or two CH 2 groups can be replaced by O or S atoms or by -CR 6 CR 6 groups and / or 1-7 H atoms by F,
• NHSO 2 A NHSO 2 Ar ', COOR 6 , CON (R 6 ) 2l CONHAr', COR 6 , COAr ', S (O) n A or S (O) n Ar' substituted phenyl or 0 naphthyl,
• p denotes 1 or 2, 5 and their salts.
• the invention relates to the hydrates and solvates of these encryption "n bonds.
• the invention was based on the task of finding new compounds with valuable properties, in particular those which can be used for the production of medicaments. 35 - 3 -
• the compounds of the formula I and their salts have very valuable pharmacological properties with good tolerability.
• they show factor Xa inhibitory properties and can therefore be used to combat and prevent thromboembolic disorders such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudication intermittently.
• Aromatic amidine derivatives with antithrombotic activity are e.g. known from EP 0 540 051 B1.
• Cyclic guanidines for the treatment of thromboembolic diseases are e.g. described in WO 97/08165.
• Aromatic heterocycles with factor Xa inhibitory activity are e.g. known from WO 96/10022.
• the antithrombotic and anticoagulant effect of the compounds according to the invention is attributed to the inhibitory effect against the activated coagulation protease, known under the name factor Xa.
• Factor Xa is one of the proteases involved in the complex process of blood clotting. Factor Xa catalyzes the conversion of prothrombin to thrombin, which in turn contributes to thrombus formation. Activation of thrombin can lead to the occurrence of thromboembolic disorders. Inhibition of factor Xa can thus prevent thrombin from being formed.
• the compounds of formula I according to the invention and their salts interfere with the blood coagulation process by inhibiting factor Xa and thus inhibit the formation of thrombi.
• the inhibition of factor Xa by the compounds according to the invention and the measurement of the anticoagulant and antithrombotic activity can be determined by customary in vitro or in vivo methods.
• a suitable method is described, for example, by J. Hauptmann et al. in Thrombosis and Haemostasis 63, 220-223 (1990).
• the measurement of the inhibition of factor Xa can, for example, by the method of T. Hara et al. in thromb. Haemostas. 71, 314-319 (1994).
• the compounds of formula I can be used as active pharmaceutical ingredients in human and veterinary medicine, in particular for combating and preventing thromboembolic disorders such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudication intermediate.
• thromboembolic disorders such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudication intermediate.
• the invention relates to the compounds of the formula I and their salts and to a process for the preparation of compounds of the formula I according to claim 1 and their salts, characterized in that
• Hydrates and solvates are e.g. the hemi, mono- or dihydrates, among solvates e.g. Alcohol addition compounds such as with methanol or ethanol.
• A means alkyl, is linear or branched, and has 1 to 20, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms.
• A is preferably methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, further also pentyl, 1-, 2- or 3-methylbutyi, 1, 1-, 1, 2 - or 2,2-dimethylpropyl, 1-ethyl propyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1, 1-, 1, 2-, 1, 3-, 2,2-, 2 , 3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1, 1, 2- or 1, 2,2-trimethylpropyl, heptyl, Octyl, nonyl or decyl.
• A also means e.
• COR 6 is acyl and preferably means formyl, acetyl, propionyl, but also butyryl, pentanoyl or hexanoyl.
• COOR 6 preferably means methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl or butoxycarbonyl.
• R 2 , R and R are each, independently of one another, preferably H, fluorine, chlorine, bromine, iodine, hydroxy, methoxy, ethoxy, propoxy, nitro, amino, methylamino, dimethylamino, ethylamino, diethylamino, acetamido, sulfonamido, methylsulfonamido , Phenylsulfonamido, methylthio, ethylthio,
• R 2 , R 5 mean H.
• R 3 in particular denotes, for example, H, COOA or -OCH 2 COOR 6 , where R 6 denotes H or alkyl having 1-4 C atoms.
• R represents H, A or benzyl, but especially H or alkyl with 1-4 C-
• Ar preferably denotes unsubstituted phenyl or naphthyl, further preferably, for example, by A, fluorine, chlorine, bromine, iodine, hydroxyl, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyioxy, benzyloxy, phenethyloxy, methylthio, ethylthio, methylsulfinyl, ethylsulfinyl, methylsulfonyl, Ethylsulfonyl, phenylsulfinyl, phenylsulfonyl, nitro, amino, methylamino, ethylamino, dimethylamino, diethylamino, formamido, acetamido, propionylamino, butyrylamino, methylsulfonamido, ethylsulfonamido, propyls
• Ar therefore preferably means, for example, o-, m- or p-tolyi, o-, m- or p-ethylphenyl, o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-tert-butylphenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-nitrophenyl, o-, m- or p-aminophenyl, o-, - or p- ( N-methylamino) phenyl, o-, m- or p-acetamidophenyl, o-, m- or p-methoxyphenyl, o-, m- or p-ethoxyphenyl, o-, m- or p-carboxyphenyl, o-,
• Ar 'means in particular, for example, phenyl or naphthyl, further preferably, for example, o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-, m- or p-propylphenyl, o-, m- or p-isopropylphenyl, o-, m- or p-tert-butylphenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-nitrophenyl, o-, m- or p-aminophenyl, o -, m- or p- (N-methylamino) phenyl, o-, m- or p-acetamido phenyl, o-, m- or p-methoxyphenyl, o-, m- or p-ethoxyphenyl,
• the invention relates in particular to those compounds of the formula I in which at least one of the radicals mentioned has one of the preferred meanings indicated above.
• Some preferred groups of compounds can be expressed by the following sub-formulas la to li, which correspond to the formula I and in which the radicals not specified have the meaning given for the formula I, but in which
• R 3 is H, COOR 6 or -O- (CH 2 ) COOR 6
• A is alkyl with 1-4 carbon atoms. - 10 -
• the starting materials can also be formed in situ, so that they are not isolated from the reaction mixture, but instead are immediately reacted further to give the compounds of the formula I.
• Compounds of the formula I can preferably be obtained by liberating compounds of the formula I from one of their functional derivatives by treatment with a soivolysing or hydrogenolysing agent.
• Preferred starting materials for solvolysis or hydrogenolysis are those which otherwise correspond to the formula I, but instead of one or more free amino and / or hydroxyl groups contain corresponding protected amino and / or hydroxyl groups, preferably those which instead of an H atom, which is connected to an N atom carry an amino protective group, in particular those which instead of an HN
• Group carry an R'-N group, in which R 'represents an amino protecting group and / or those which carry a hydroxy protecting group instead of the H atom of a hydroxy group, e.g. those which correspond to the formula I, but carry parts of a group -COOH a group -COOR ", in which R" denotes a hydroxy protective group.
• Preferred starting materials are also the oxadiazole derivatives, which can be converted into the corresponding amidino compounds.
• the oxadiazole group can be introduced, for example, by reacting the cyano compounds with hydroxylamine and reaction with phosgene, dialkylamine. - 11 -
• amino protecting group is generally known and refers to groups which are suitable for protecting (blocking) an amino group from chemical reactions, but which are easily removable after the desired chemical reaction has been carried out at other locations in the molecule. Unsubstituted or substituted acyl, aryl, aralkoxymethyl or aralkyl groups are particularly typical of such groups. Since the amino protective groups are removed after the desired reaction (or reaction sequence), their type and size is otherwise not critical; however, preference is given to those having 1-20, in particular 1-8, carbon atoms.
• acyl group is to be understood in the broadest sense in connection with the present process.
• acyl groups derived from aliphatic, araliphatic, aromatic or heterocyclic carboxylic acids or sulfonic acids, and in particular alkoxycarbonyl, aryloxycarbonyl and especially aralkoxycarbonyl groups.
• acyl groups are alkanoyl such as acetyl, propionyl, butyryl; Aralkanoyl such as phenylacetyl; Aroyl such as benzoyl or toluyl; Aryloxyalkanoyl such as POA; Alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOC (tert-butyloxycarbonyl), 2-iodoethoxycarbonyl; Aralkyloxycarbonyl such as CBZ ("carbobenzoxy"), 4-methoxybenzyloxycarbonyl, FMOC; Arylsulfonyl such as Mtr.
• Preferred amino protective groups are BOC and Mtr, furthermore CBZ, Fmoc, benzyl and acetyl.
• hydroxyl protecting group is also generally known and refers to groups which are suitable for protecting a hydroxyl group against chemical reactions, but which are easily removable after the desired chemical reaction has been carried out at other locations in the molecule. Typical of such groups are those above - 12 -
• hydroxyl protective groups are not critical since they are removed again after the desired chemical reaction or reaction sequence; groups with 1-20, in particular 1-10, carbon atoms are preferred.
• hydroxy protecting groups include Benzyl, p-nitrobenzoyl, p-toluenesulfonyl, tert-butyl and acetyl, with benzyl and tert-butyl being particularly preferred.
• Suitable inert solvents are preferably organic, for example carboxylic acids such as acetic acid, ethers such as tetrahydrofuran or dioxane, amides such as DMF, halogenated hydrocarbons such as dichloromethane, and also alcohols such as methanol, ethanol or isopropanol, and water. Mixtures of the abovementioned solvents are also suitable. TFA is preferably used in excess without the addition of another solvent, perchloric acid in the form of a mixture of acetic acid and 70% perchloric acid in a ratio of 9: 1.
• the reaction temperatures for the cleavage are advantageously between about 0 and about 50 °, preferably between 15 and 30 ° (room temperature).
• the groups BOC, OBut and Mtr can e.g. B. preferably with TFA in dichloromethane or with about 3 to 5N HCl in dioxane at 15-30 °, the FMOC group with an about 5 to 50% solution of dimethylamine, diethylamine or piperidine in DMF at 15-30 °.
• Hydrogenolytically removable protective groups e.g. CBZ, benzyl or the liberation of the amidino group from their oxadiazolde vat
• a catalyst z. B. a noble metal catalyst such as palladium, suitably on a support such as coal or like wet Raney nickel with the addition of, for example, acetic acid - 13 -
• Suitable solvents are the above, especially z.
• the hydrogenolysis is generally carried out at temperatures between about 0 and 100 ° and pressures between about 1 and 200 bar, preferably at 20-30 ° and 1-10 bar. Hydrogenolysis of
• CBZ Group succeeds e.g. B. good on 5 to 10% Pd / C in methanol or with ammonium formate (instead of hydrogen) on Pd / C in methanol / DMF at 20-30 °.
• the conversion of a cyano group into an amidino group takes place by reaction with e.g. Hydroxylamine and subsequent reduction of the N-hydroxyamidine with hydrogen in the presence of a catalyst such as e.g. Pd / C or Raney nickel.
• a catalyst such as e.g. Pd / C or Raney nickel.
• the addition is preferably carried out in several stages by, in a manner known per se, a) converting the nitrile with H 2 S into a thioamide, which is converted into the corresponding S-alkylimidothioester using an alkylating agent, for example CH 3 I in turn reacts with NH 3 to form the amidine, b) converting the nitrile with an alcohol, for example ethanoi in the presence of HCl, into the corresponding imidoester and treating it with ammonia, or c) reacting the nitrile with lithium bis (trimethylsilyl) amide and the product then hydrolyzed.
• the cyan compounds are prepared by methods known per se.
• Esters can e.g. are saponified with acetic acid or with NaOH or KOH in water, water-THF or water-dioxane at temperatures between 0 and 100 °.
• free amino groups can be acylated in the usual way with an acid chloride or anhydride or alkylated with an unsubstituted or substituted alkyl halide, advantageously in an inert solvent such as dichloromethane or THF and / or in the presence of a base such as triethylamine or pyridine at temperatures between -60 and
• the reaction is usually carried out in an inert solvent, in the presence of an acid-binding agent, preferably an alkali metal or alkaline earth metal hydroxide, carbonate or bicarbonate or another salt of a weak acid of the alkali metal or alkaline earth metal, preferably potassium, sodium , Calcium or cesium.
• an organic base such as triethylamine, dimethylaniline, pyridine or quinoline or an excess of the amine component of the formula II or the alkylation derivative of the formula III can also be favorable.
• the reaction time is between a few minutes and 14 days, the reaction temperature is between about 0 ° and 150 °, normally between 20 ° and 130 °.
• Suitable inert solvents are, for example, hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichlorethylene, 1, 2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; Alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; Ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; Glycol ethers such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene - 15 -
• hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene
• chlorinated hydrocarbons such as
• glycol dimethyl ether diglyme
• Ketones such as acetone or butanone
• Amides such as acetamide, dimethylacetamide, N-methyipyrrolidone (NMP) or dimethylformamide (DMF)
• Nitriles such as acetonitrile
• Sulfoxides such as dimethyl sulfoxide (DMSO)
• Carbon disulfide Carboxylic acids such as formic acid or acetic acid
• Nitro compounds such as nitromethane or nitrobenzene; Esters like
• a base of the formula I can be converted into the associated acid addition acid using an acid, for example by reacting equivalent amounts of the base and the acid in an inert solvent such as ethanoi and subsequent evaporation.
• acids that provide physiologically acceptable salts are suitable for this implementation.
• So inorganic acids can be used, e.g. Sulfuric acid, nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, also organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or polybasic carboxylic, sulfonic or sulfuric acids, e.g.
• compounds of formula I with bases can be converted into the corresponding metal, in particular alkali metal or alkaline earth metal, or into the corresponding ammonium salts.
• Physiologically harmless organic bases such as ethanol amine, can also be used. - 16 -
• the invention further relates to the use of the compounds of the formula I and / or their physiologically acceptable salts for the production of pharmaceutical preparations, in particular by a non-chemical route.
• they can be brought into a suitable dosage form together with at least one solid, liquid and / or semi-liquid carrier or auxiliary and optionally in combination with one or more further active ingredients.
• the invention further relates to pharmaceutical preparations containing at least one compound of the formula I and / or one of its physiologically acceptable salts.
• Suitable carriers are organic or inorganic substances which are suitable for enteral (for example oral), parenteral or topical application and do not react with the new compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin , Carbohydrates such as lactose or starch, magnesium stearate, talc, petroleum jelly.
• Tablets, pills, dragees, capsules, powders, granules, syrups, juices or drops are used for oral use, suppositories for rectal use, solutions, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants for topical use for parenteral use Ointments, creams or powder.
• the new compounds can also be lyophilized and the lyophilizates obtained e.g. can be used for the production of injectables.
• the specified preparations can be sterilized and / or contain auxiliaries such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, coloring, flavoring and / or several other active substances, e.g. one or more vitamins.
• auxiliaries such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, coloring, flavoring and / or several other active substances, e.g. one or more vitamins.
• the compounds of the formula I and their physiologically acceptable salts can be used in the control and prevention of thromboembolic disorders such as thrombosis, myocardial infarction, arteriosclero- - 17 -
• the substances according to the invention are generally preferably administered in doses between about 1 and 500 mg, in particular between 5 and 100 mg, per dosage unit.
• the daily dosage is preferably between about 0.02 and 10 mg / kg body weight.
• the specific dose for each patient depends on a wide variety of factors, for example on the effectiveness of the particular compound used, on the age, body weight, general health, sex, on the diet, on the time and route of administration, on the rate of elimination and combination of drugs and severity of the disease to which the therapy applies. Oral application is preferred.
• a solution of 2.06 g of 3-bromobenzonitrile and 1.50 g of 3-tolylboronic acid in 50 ml of dimethoxyethane is mixed with 247 mg of palladium (II) acetate, 335 mg of tri-o-toiylphosphine, 20 ml of water and 954 mg of anhydrous sodium carbonate added and heated with stirring at 100 ° C for 18 hours.
• the mixture is worked up in the customary manner, the residue is chromatographed on a silica gel column with petroleum ether / ethyl acetate 9: 1 and 3'-methylbiphenyl-3-carbonitrile is obtained as a colorless solid ("A”), El 193.
• the compound 3'-cyano-5-methyl-biphenyl-3-carboxylic acid methyl ester is obtained by reacting 3-cyanophenylboronic acid with methyl 3-bromo-5-methylbenzoate. Bromination with NBS and reaction with 3-hydroxybenzonitrile gives 3'-cyan-5- (3-cyanophenoxymethyl) biphenyl-3-carboxylic acid methyl ester. Reaction with hydroxyiamine and reduction with H 2 / Ra-Ni gives the compound 3'-carbamimidoyl-5- (3-carbamimidoyl-phenoxymethyl) biphenyl-3-carboxylic acid methyl ester. - 20th
• tert-butyl ester are cleaved with trifluoroacetic acid and the corresponding carboxylic acids are obtained
• a solution of 5.0 g of 3'-bromomethyl-biphenyl-3-carbonitrile and 5 ml of triethyl phosphite are combined and slowly heated to 150 °.
• the mixture is subsequently stirred at 150 ° for 6 h and, after customary working up, 6.05 g of diethyl 3-cyano-biphenyl-3-ylmethylphosphonate ("BA”) are obtained.
• 150 mg of sodium hydride are added to a solution of 1.0 g of “BA” and 3-cyanobenzaldehyde in 20 ml of ethylene glycol dimethyl ether with ice cooling and nitrogen.
• the mixture is stirred for 4 hours, worked as usual and 0.93 g of 3 '- [2- (3-cyanophenyl) vinyl] biphenyl-3-carbonitrile (“BB”) is obtained.
• Example A Injection glasses
• a solution of 100 g of an active ingredient of the formula I and 5 g of disodium hydrogenphosphate is adjusted to pH 6.5 in 3 l of double-distilled water with 2N hydrochloric acid, sterile filtered, filled into injection glasses, lyophilized under sterile conditions and sealed sterile. Each injection jar contains 5 mg of active ingredient.
• a mixture of 20 g of an active ingredient of the formula I is melted with 100 g of soy lecithin and 1400 g of cocoa butter, poured into molds and allowed to cool. Each suppository contains 20 mg of active ingredient.
• a solution is prepared from 1 g of an active ingredient of the formula I, 9.38 g of NaH 2 PO 4 .2H 2 O, 28.48 g of Na 2 HPO 4 .12H 2 O and 0.1 g of benzalkonium chloride in 940 ml of double distilled water. It is adjusted to pH 6.8, made up to 1 I and sterilized by irradiation. This solution can be used in the form of eye drops.
• Example D ointment
• 500 mg of an active ingredient of the formula I are mixed with 99.5 g of petroleum jelly under aseptic conditions.
• a mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose, 1, 2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed into tablets in a conventional manner such that each tablet contains 10 mg of active ingredient.
• Example F coated tablets
• Example E tablets are pressed, which are then coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and colorant.
• Example G capsules
• each capsule contains 20 mg of the active ingredient.
• a solution of 1 kg of active ingredient of the formula I in 60 l of double-distilled water is sterile filtered, filled into ampoules, lyophilized under sterile conditions and sealed sterile. Each ampoule contains 10 mg of active ingredient.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Public Health (AREA)
• General Chemical & Material Sciences (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=7866421

Family Applications (1)

Country Status (19)

Families Citing this family (8)

Family Cites Families (6)

• 1998
  • 1998-04-30 DE DE19819548A patent/DE19819548A1/de not_active Withdrawn
• 1999
  • 1999-04-12 EP EP99920646A patent/EP1076643A1/de not_active Withdrawn
  • 1999-04-12 HU HU0102220A patent/HUP0102220A3/hu unknown
  • 1999-04-12 CA CA002328732A patent/CA2328732A1/en not_active Abandoned
  • 1999-04-12 BR BR9910021-5A patent/BR9910021A/pt not_active IP Right Cessation
  • 1999-04-12 PL PL99343598A patent/PL343598A1/xx unknown
  • 1999-04-12 KR KR1020007011315A patent/KR20010052249A/ko not_active Application Discontinuation
  • 1999-04-12 RU RU2000129159/04A patent/RU2219166C2/ru not_active IP Right Cessation
  • 1999-04-12 ID IDW20002341A patent/ID27152A/id unknown
  • 1999-04-12 AU AU38154/99A patent/AU750472B2/en not_active Ceased
  • 1999-04-12 CN CN99805661A patent/CN1299343A/zh active Pending
  • 1999-04-12 WO PCT/EP1999/002457 patent/WO1999057096A1/de not_active Application Discontinuation
  • 1999-04-12 JP JP2000547066A patent/JP2002513780A/ja active Pending
  • 1999-04-12 US US09/674,267 patent/US6380430B1/en not_active Expired - Fee Related
  • 1999-04-12 SK SK1596-2000A patent/SK15962000A3/sk unknown
  • 1999-04-30 AR ARP990102014A patent/AR019264A1/es not_active Application Discontinuation
  • 1999-12-04 UA UA2000116686A patent/UA58593C2/uk unknown
• 2000
  • 2000-10-27 NO NO20005435A patent/NO20005435L/no not_active Application Discontinuation
  • 2000-11-29 ZA ZA200007039A patent/ZA200007039B/en unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events